(Q45869314)

17 December 2017

title

Safety and pharmacokinetics of subcutaneously administered recombinant activated factor VII (rFVIIa). (English)

1 reference

17 December 2017

1 reference

G Allen

4

0 references

Andreas Tiede

object named as

A Tiede

1

0 references

Claude Negrier

object named as

C Negrier

13

0 references

Valerie Chamouard

0 references

author name string

U Friedrich

2

1 reference

17 December 2017

C Stenmo

3

1 reference

17 December 2017

P Giangrande

5

1 reference

17 December 2017

J Goudemand

6

1 reference

17 December 2017

C Hay

7

1 reference

17 December 2017

M Holmström

8

1 reference

17 December 2017

R Klamroth

9

1 reference

17 December 2017

S Lethagen

10

1 reference

17 December 2017

S McKenzie

11

1 reference

17 December 2017

W Miesbach

12

1 reference

17 December 2017

V J Yuste

14

1 reference

17 December 2017

E Berntorp

15

1 reference

17 December 2017

language of work or name

1 reference

1 June 2011

1 reference

17 December 2017

Journal of Thrombosis and Haemostasis

published in

1 reference

17 December 2017

volume

9

1 reference

17 December 2017

issue

6

1 reference

17 December 2017

page(s)

1191-1199

1 reference

17 December 2017

Mechanism of action, development and clinical experience of recombinant FVIIa

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2011.04293.X

Mechanism of action of recombinant activated factor VII: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2011.04293.X

Secondary prophylaxis with recombinant activated factor VII improves health-related quality of life of haemophilia patients with inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2011.04293.X

Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2011.04293.X

Subcutaneous versus intravenous administration of heparin in the treatment of deep vein thrombosis; which do patients prefer? A randomized cross-over study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2011.04293.X

Reduced bleeding events with subcutaneous administration of recombinant human factor IX in immune-tolerant hemophilia B dogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2011.04293.X

Subcutaneous factor IX administration to patients with hemophilia B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2011.04293.X

Subcutaneous injection of factor IX for the treatment of haemophilia B

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2011.04293.X

Safety update on the use of recombinant factor VIIa and the treatment of congenital and acquired deficiency of factor VIII or IX with inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2011.04293.X

Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: analysis from the Hemophilia and Thrombosis Research Society Registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2011.04293.X

Recombinant factor VIIa (eptacog alfa): a review of its use in congenital hemophilia with inhibitors, acquired hemophilia, and other congenital bleeding disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2011.04293.X

Managing acute bleeds in the patient with haemophilia and inhibitors: options, efficacy and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2011.04293.X

Comparison of coagulant activity of factor VII and activated factor VII activity assays when used for determination of recombinant activated factor VII levels in plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2011.04293.X

Confidence interval criteria for assessment of dose proportionality.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2011.04293.X

Novel delivery systems for coagulation proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2011.04293.X

Prophylaxis in 10 patients with severe haemophilia A and inhibitor: different approaches for different clinical situations

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2011.04293.X

Prophylactic treatment of haemophilia patients with inhibitors: clinical experience with recombinant factor VIIa in European Haemophilia Centres.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2011.04293.X

Successful treatment of canine hemophilia by continuous expression of canine FVIIa

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2011.04293.X

Thrombin generation in vitro in the presence of by-passing agents in siblings with severe haemophilia A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2011.04293.X

Enhancement of factor VIIa haemostatic efficacy by formulation with PEGylated liposomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2011.04293.X

Recombinant factor VIIa: review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2011.04293.X

10.1111/J.1538-7836.2011.04293.X

21 January 2018

Identifiers

DOI

1 reference

17 December 2017

1 reference

17 December 2017